Sanofi Profit May Drop This Year as Lantus Blockbuster Ages

Sanofi Profit May Drop This Year as Lantus Blockbuster Ages

This post was originally published on this site

Sanofi said profit may drop this year as the French drugmaker pursues new drivers of growth to offset declines for its best-selling diabetes treatment Lantus. Sanofi expects earnings per share excluding some items to be stable to down as much as 3 percent at constant exchange rates, the Paris-based company said in a statement on Wednesday.